Semaglutide's FDA Cardiovascular Nod Drives Short-Term Uptick, Leaves Treatment Gaps
Event summary
- FDA expanded semaglutide's cardiovascular indication in March 2024, leading to a 23% immediate increase in first-time dispensing.
- Semaglutide's initial uptake declined gradually, while tirzepatide saw steady, sustained growth despite lacking a cardiovascular indication.
- Less than 1% of eligible adults with cardiovascular disease and overweight/obesity initiated either therapy during the study period (Jan 2021-May 2025).
- Study analyzed 2M+ US adults using Truveta Data, combining EHR and pharmacy dispensing data from leading health systems.
The big picture
The study highlights the disconnect between regulatory approvals and real-world adoption of high-cost cardiometabolic therapies. While semaglutide saw an initial boost from its cardiovascular indication, persistent treatment gaps suggest systemic barriers. The diverging trends between semaglutide and tirzepatide point to evolving prescribing behaviors and patient preferences that could reshape this market segment.
What we're watching
- Regulatory Impact
- How FDA approvals will affect long-term adoption of cardiometabolic therapies among high-risk patients.
- Market Dynamics
- Whether tirzepatide can sustain its growth trajectory without a cardiovascular indication.
- Access Barriers
- The pace at which payers and health systems address affordability and workflow challenges for these therapies.
Related topics